Selling Semaglutide Products Compliantly

let us start with the sentence that decides everything downstream: in the united states, semaglutide is a prescription drug. it is not a supplement, it is not a wellness product, and it is not something you can put in a shopify cart and ship. if your business model requires that sentence to be false, you do not have a business model. everything that follows assumes you are building around it, not around it.

this is also, by a wide margin, the largest demand curve any of us will work with in this category. glp-1 search volume, med spa inquiry volume, and consumer willingness to pay are all at levels the aesthetics industry has never seen. so the question is not whether to participate. it is how to participate in a structure that survives more than eighteen months. nothing here is medical or legal advice — you need licensed providers and a healthcare attorney.

the three structures operators actually use

there are broadly three ways brands and med spas have participated in the glp-1 market, and they carry very different risk profiles.

1. 1.brand-name dispensing under a licensed provider — lowest regulatory ambiguity, thinnest margin, supply-dependent, and you are competing with retail pharmacy and manufacturer direct programs
2. 2.compounded semaglutide through a licensed pharmacy under a valid patient-specific prescription — the model most med spas built on, and the one under the most sustained scrutiny as shortage-era flexibility narrowed
3. 3.the research-use-only gray channel — cheapest, most profitable on paper, and the one we tell operators to stay out of, because selling a prescription drug analog to consumers under an RUO label is exactly the fact pattern regulators and processors act on

if you are building something you intend to sell or scale, structure one and two are the conversation. the compounded path in particular has moved a lot: as shortage designations resolved, the latitude compounders had narrowed considerably, and the rules around what counts as a permissible personalized formulation versus an essentially-a-copy product are the specific thing your attorney needs to be current on. that answer changes. do not rely on what was true when you started.

you are building a medical business, not a product business

this is the mental shift that separates operators who scale from operators who get letters. a compliant glp-1 offer is a care model. there is an intake, a licensed provider who is actually licensed in the patient's state, a real evaluation, a prescription decision that the provider can decline, documented follow-up, adverse event reporting, and a pharmacy relationship. the ecommerce layer is packaging around that. it is not the product.

• —provider licensure must be mapped state by state, and your funnel has to gate by state before it takes money
• —your intake must be a real clinical intake, not a formality designed to always say yes — a provider who never declines is a compliance finding waiting to happen
• —corporate practice of medicine rules mean your entity structure matters; MSO and PC arrangements exist for a reason and need to be papered correctly
• —telehealth rules, prescribing rules, and pharmacy rules are three separate bodies of law and all three apply
• —adverse event intake and escalation has to exist before your first patient, not after your first incident

the operators who get this right build the medical layer first and then wrap acquisition around it. the ones who get it wrong build a funnel, bolt a provider onto it, and discover that the provider was the entire business.

payments are the failure point nobody plans for

we have watched more glp-1 businesses die from payment processing than from regulators. the pattern is consistent: a brand launches on a standard low-risk processor, scales fast, gets flagged for prescription-adjacent products or elevated chargebacks, and has their funds held for 90 to 180 days at exactly the moment they have inventory and ad spend committed. that is a solvency event, not an inconvenience.

build for it up front. that means a high-risk merchant account with a processor that knows what telehealth and prescription products are, disclosed accurately at underwriting rather than described vaguely to get approved. it means a backup processor with live volume so failover is real. it means chargeback prevention tooling, clear billing descriptors, obvious cancellation paths, and a refund policy you actually honor — subscription glp-1 programs generate disputes and your dispute rate is the number that gets you shut off.

marketing under Meta's weight loss policy

meta treats weight loss as a sensitive category and enforces it hard. the practical constraints: no before-and-after imagery, no implied guaranteed outcomes, no body shaming or negative self-perception framing, no ad copy that assumes a personal attribute about the viewer, and age restrictions on targeting. accounts running this category get restricted routinely, and once you are restricted, appeals are slow.

the creative that actually performs inside those rules is not the creative most operators try first. it is process-led and identity-led rather than result-led: what the program includes, what the provider visit looks like, how fast you get an answer, what happens if you are not a fit, what the follow-up cadence is. that content is compliant and it also converts better, because the objection in this market is not whether glp-1s work — the market decided that — it is whether your program is legitimate.

• —sell the care model: licensed providers, real evaluation, ongoing follow-up, transparent pricing
• —no before-and-afters, no scale photos, no number-of-pounds promises, no you-language about the viewer's body
• —run a large volume of live creative so individual rejections do not stall the account — 294 concurrent ads is a normal working number for us
• —keep landing page claims tighter than your ad claims, because policy review reads the page too
• —build email and sms hard; the moment paid gets restricted, owned channel revenue is what keeps you alive

margins and program design

glp-1 economics are strong but not automatic. the biggest lever is not price per vial, it is program design and retention. a monthly program with a real care cadence retains dramatically better than a transactional refill, and retention is where the margin is, because your acquisition cost is fully loaded into month one.

model your unit economics per patient month, not per unit sold: product cost, pharmacy fees, provider compensation per encounter, platform and ehr costs, shipping including any cold chain, processing at high-risk rates, and support labor. then compare that to your blended cac and your observed month-three and month-six retention. a lot of programs that look profitable on a first-order basis are underwater once you count the provider time on months two through six.

common mistakes

1. 1.treating the provider layer as a checkbox instead of the core of the business
2. 2.not gating by state, and dispensing into states where your provider is not licensed
3. 3.launching on a low-risk processor and getting frozen at the worst possible moment
4. 4.running result-based creative because it works for two weeks, then losing the ad account
5. 5.assuming the compounding rules that applied at launch still apply — this area moves and you need current counsel
6. 6.building no owned-channel revenue, so a single platform restriction removes all demand

in glp-1, the ad account is rented and the medical structure is owned. build the thing you own first.

how this fits a broader peptide catalog

for med spas, semaglutide is usually the demand engine and the rest of the catalog is the margin. a glp-1 patient is a high-intent, high-frequency, high-trust customer who is already transacting with you monthly. the attach products, the aesthetic services, the memberships, and the non-prescription categories all perform better against that base than against cold traffic. just keep the compliance regimes separate — a prescription program and a research-use-only product line should not share claims, checkout language, or creative.